LLY and VRTX Related Headlines
Go Back- Leerink highlights drug demand rebound after Memorial Day
- Bernstein on US Pharma and Biotech: Who might buy whom?
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
- Citi initiates coverage on biotech amid improving sentiment in sector
